AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Stock Short Interest Drops 49.1%

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 1,407,198 shares, a decrease of 49.1% from the September 15th total of 2,765,187 shares. Based on an average trading volume of 1,866,131 shares, the days-to-cover ratio is presently 0.8 days. Currently, 4.7% of the company’s shares are sold short.

AIM ImmunoTech Stock Performance

NYSEAMERICAN:AIM traded down $0.00 on Friday, hitting $0.17. 337,515 shares of the stock were exchanged, compared to its average volume of 11,611,004. AIM ImmunoTech has a 52 week low of $0.16 and a 52 week high of $2.88. The stock has a market capitalization of $5.12 million, a price-to-earnings ratio of -0.05 and a beta of 1.27. The company’s 50-day moving average price is $0.22 and its 200 day moving average price is $0.34.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.43) EPS for the quarter. The firm had revenue of $0.03 million for the quarter. As a group, equities research analysts predict that AIM ImmunoTech will post -0.78 earnings per share for the current year.

About AIM ImmunoTech

AIM ImmunoTech Inc is a clinical-stage immuno-pharmaceutical company focused on developing therapies that activate and regulate the immune system. The company’s research programs target cancer, viral diseases and other conditions in which immune-system activity may play a role in disease progression or treatment response.

AIM’s principal investigational product is Ampligen (rintatolimod), a double-stranded RNA-based immune modulator designed to stimulate antiviral and antitumor immune responses.